Pharma Mar Sau Stock Performance
| PHMMF Stock | USD 88.72 1.84 2.03% |
Pharma Mar has a performance score of 7 on a scale of 0 to 100. The company holds a Beta of 0.28, which implies not very significant fluctuations relative to the market. As returns on the market increase, Pharma Mar's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pharma Mar is expected to be smaller as well. Pharma Mar SAU right now holds a risk of 0.67%. Please check Pharma Mar SAU variance, as well as the relationship between the value at risk and day median price , to decide if Pharma Mar SAU will be following its historical price patterns.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Pharma Mar SAU are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable primary indicators, Pharma Mar is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 96.2 M | |
| Total Cashflows From Investing Activities | 18.5 M |
Pharma |
Pharma Mar Relative Risk vs. Return Landscape
If you would invest 8,534 in Pharma Mar SAU on November 13, 2025 and sell it today you would earn a total of 338.00 from holding Pharma Mar SAU or generate 3.96% return on investment over 90 days. Pharma Mar SAU is currently producing 0.0669% returns and takes up 0.6692% volatility of returns over 90 trading days. Put another way, 6% of traded pink sheets are less volatile than Pharma, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Pharma Mar Target Price Odds to finish over Current Price
The tendency of Pharma Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 88.72 | 90 days | 88.72 | about 40.09 |
Based on a normal probability distribution, the odds of Pharma Mar to move above the current price in 90 days from now is about 40.09 (This Pharma Mar SAU probability density function shows the probability of Pharma Pink Sheet to fall within a particular range of prices over 90 days) .
Pharma Mar Price Density |
| Price |
Predictive Modules for Pharma Mar
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pharma Mar SAU. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Pharma Mar Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pharma Mar is not an exception. The market had few large corrections towards the Pharma Mar's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pharma Mar SAU, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pharma Mar within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.1 | |
β | Beta against Dow Jones | 0.28 | |
σ | Overall volatility | 2.39 | |
Ir | Information ratio | -0.14 |
Pharma Mar Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pharma Mar for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pharma Mar SAU can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| About 27.0% of the company outstanding shares are owned by corporate insiders |
Pharma Mar Fundamentals Growth
Pharma Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Pharma Mar, and Pharma Mar fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharma Pink Sheet performance.
| Return On Equity | 0.47 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.35 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 1.12 B | |||
| Shares Outstanding | 18.09 M | |||
| Price To Earning | 7.38 X | |||
| Price To Book | 5.60 X | |||
| Price To Sales | 5.57 X | |||
| Revenue | 229.83 M | |||
| EBITDA | 104.08 M | |||
| Cash And Equivalents | 196.7 M | |||
| Cash Per Share | 10.92 X | |||
| Total Debt | 33.39 M | |||
| Debt To Equity | 0.21 % | |||
| Book Value Per Share | 9.88 X | |||
| Cash Flow From Operations | 25.68 M | |||
| Earnings Per Share | 4.97 X | |||
| Total Asset | 368.39 M | |||
| Retained Earnings | (17 M) | |||
| Current Asset | 110 M | |||
| Current Liabilities | 78 M | |||
About Pharma Mar Performance
By analyzing Pharma Mar's fundamental ratios, stakeholders can gain valuable insights into Pharma Mar's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pharma Mar has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharma Mar has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company was incorporated in 1986 and is based in Madrid, Spain. Pharma Mar operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 477 people.Things to note about Pharma Mar SAU performance evaluation
Checking the ongoing alerts about Pharma Mar for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pharma Mar SAU help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 27.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Pharma Mar's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharma Mar's stock is overvalued or undervalued compared to its peers.
- Examining Pharma Mar's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharma Mar's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharma Mar's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharma Mar's pink sheet. These opinions can provide insight into Pharma Mar's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pharma Pink Sheet analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |